Abstract:Graft versus host disease (GVHD) is caused by infused donor T cells that primarily target specific organs, such as skin, liver and intestine. While it has been demonstrated that chemokines are critical to directing in vivo trafficking of host-reactive donor T cells into GVHD target organs, blocking GVHD using antagonist antibody (Ab) against chemokine receptors remains an elusive goal. We found that in vivo administration of anti-CXCR3 Ab for 1 week (named short-term treatment) only partially prevented acute GVHD in B6/SJL mice receiving donor C3H.SW naïve CD8+ T cells, with 45% of them dying from the disease. Flow cytometry analysis showed that CXCR3+ CD8+ T cells occurred in the spleens and livers of these GVHD B6/SJL mice by day 3 and peaked by day 7 after transplantation, and persisted throughout the disease course. When donor CXCR3+ CD8+ T cells were recovered from these GVHD B6/SJL recipients at day 14 after transplantation (named day-14 CXCR3+ CD8+ T cells) and adoptively transferred into secondary B6/SJL mice, they caused severe GVHD in these secondary recipients with 90% mortality. Interestingly, short-term treatment using anti-CXCR3 Ab protected 78% of B6/SJL mice receiving these donor day-14 CXCR3+ CD8+ T cells. Thus, besides CXCR3+ T cells, some other pathogenic T cells have developed during GVH reactions. We found that a substantial population of CXCR3− CD8+ T cells occurred by day 14 (termed day-14 CXCR3− CD8+ T cells) after transplantation in the spleens (71.1%) and livers (81.6%) of B6/SJL recipients with ongoing GVHD. As compared to donor day-14 CXCR3+ CD8+ T cells, donor day-14 CXCR3− CD8+ T cells expressed lower levels of CCR2, CCR3, CCR5, CD127, granzyme B and FasL, and produced less IFN-g and TNF-a. Furthermore, adoptive transfer of donor day-14 CXCR3− CD8+ T cells caused delayed onset of GVHD as compared to those recipients of day-14 CXCR3+ CD8+ T cells, with 55% of them dying from the diseases. Prolonged treatment of B6 mice receiving day-14 CXCR3− CD8+ T cells with anti-CXCR3 Ab up to 3 weeks (named long-term treatment) significantly inhibited the development of GVHD. More than 70% of these recipients survived without clinical signs of GVHD. In vivo experiments showed that 23% of day-14 CXCR3− CD8+ T cells were converted into CXCR3+ by 12 hours after adoptive transfer into B6/SJL recipients, and up to 60% by 24 hours. Interestingly, about 25% of CXCR3+ CD8+ T cells were also converted into CXCR3− by 24 hours after their transfer. We found in ex vivo cultures that both dendritic cells and interleukin-2 accounted for this conversion between CXCR3+ and CXCR3− subsets, which was inhibited by addition of Ab specific to MHC-I or CTLA-4 Ig. Taken together, these results suggest that alloantigen-induced repression of chemokine receptor(s) may present a major barrier to the success of GVHD prevention and treatment when using antagonists against chemokines or chemokine receptors.

Chemokines and Chemokine Receptors Expressed by the Liver and Allo-Reactive CD8+ T Cells in Graft-Versus-host Disease Mouse

Down Regulation Of Cxc Chemokine Receptor 3 Impedes The Ability Of Anti-Cxcr3 Antibody To Block Graft-Versus-Host Disease

Chemokines and Chemokine Receptors Induced Lymphocyte Migration and Graft-versus-host Disease

A new approach to the blocking of alloreactive T cell-mediated graft-versus-host disease by in vivo administration of anti-CXCR3 neutralizing antibody.

Therapeutic effect of CXCR3-expressing regulatory T cells on liver, lung and intestinal damages in a murine acute GVHD model

Association of Chemokine Receptor CCR5, CCR6 and CCR7 Expressions on T Lymphocyte Subsets in Recipients after Allo-HSCT with Acute GvHD

Chemokine receptor CCR5 mediates alloimmune responses in graft-versus-host disease

Influence of the lentiviral vectors-mediated mouse genetic engineering Treg after allogeneic bone marrow transplantation on graft-versus-hostdiseaseinmice

γδ T Cells May Aggravate Acute Graft-Versus-Host Disease Through CXCR4 Signaling After Allogeneic Hematopoietic Transplantation

[Influence of Mouse Genetic Engineering Regulatory T Cells Infusion on Post-Allogeneic Bone Marrow Transplantation Acute Graft-Versus-host Disease in Mice].

[Chemokine Receptor-5 and Graft-versus-Host Disease].

Role of Dendritic Cells and Chemokines in Acute Graft-Versus-host Disease.

CXCR4-transduced Mesenchymal Stem Cells Protect Mice Against Graft-Versus-host Disease.

Assessing Cell Chimerism in an Acute Graft-Versus-host Disease Model Established in TLR4 Knockout Mice.

Chemokines in Chronic Liver Allograft Dysfunction Pathogenesis and Potential Therapeutic Targets

[Alteration of Chemokines after Allogeneic Hematopoietic Stem Cell Transplantation and Its Clinical Significance].

Chemokine receptors are required for effector T cell trafficking to GVHD tissues but not to bone marrow

Establishment of Mouse Model of CD8+T Cell-mediated Acute Graft Versus Host Disease

Study on the Relationship Between Memory CD8+T Cell and GVHD

Expansion kinetics of graft‐versus‐host T cell clones in patients with post‐liver transplant graft‐versus‐host disease

Dynamic Regulation of Effector IFN-γ-producing and IL-17-producing T Cell Subsets in the Development of Acute Graft-Versus-host Disease